SCHEMBL6726852

SCHEMBL6726852

[C-]#[N+]c1c(N2CCO[C@H](CF)C2)sc(-c2nnc[nH]2)c1-c1ccc(Cl)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.39
MTOR P42345 1/20 0.39
PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726827 1.00 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726821 1.00 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726836 0.92 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726847 0.92 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726822 0.92 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726816 0.92 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726848 0.92 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726856 0.92 PIK3CA (0.39) PIK3CAMTORPPARA
SCHEMBL6726855 0.91 PIK3CA (0.38) PIK3CAMTOR
SCHEMBL6726851 0.88 PIK3CA (0.41) PIK3CAMTORPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130217689-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-08-22 US disclosed
US-8440664-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-20120202812-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-08-09 US disclosed
US-8183240-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-05-22 US disclosed
US-20100075951-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075951-A1 Heteroaryls and uses thereof PIK3R3, AKT1S1, PIK3R1 PIK3CA 11/4885MTOR 148/4885PPARA 1404/4885
US-20130217689-A1 HETEROARYLS AND USES THEREOF PIK3R3, AKT1S1, PIK3R1 PIK3CA 11/4885MTOR 148/4885PPARA 1404/4885
US-20120202812-A1 HETEROARYLS AND USES THEREOF PIK3R3, AKT1S1, PIK3R1 PIK3CA 11/4885MTOR 148/4885PPARA 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.